Contraception in Advanced CKD, Diabetes, Prior VTE, and Heavy Bleeding
43-year-old G3P3 with type 2 diabetes (A1c 9.1%), stage 4 chronic kidney disease (eGFR 22), and hypertension (158/96 on lisinopril and amlodipine) requests contraception. She has a history of postpartum deep vein thrombosis after her last cesarean and a BMI of 38. Her periods are heavy and she has iron-deficiency anemia (hemoglobin 8.9 g/dL). She is unsure about sterilization and says she wants “something I don't have to think about.” She is not currently pregnant and has no plans for pregnancy.
1. Which methods are contraindicated or preferred? Explain using medical eligibility criteria.
Read the worked answer
Combined hormonal contraception is category 4 for her because of prior VTE and diabetes with probable nephropathy; her hypertension is also category 3 and close to the category 4 threshold. Estrogen-containing methods are therefore not appropriate. Progestin-only methods are generally safer: the etonogestrel implant and levonorgestrel IUD are category 1/2, and DMPA is category 2 but may worsen bone density and is less ideal in advanced CKD. The copper IUD is category 1 but can worsen heavy bleeding and anemia.
The 52-mg LNG-IUD is the preferred option because it is highly effective, does not increase VTE risk, and treats heavy menstrual bleeding. Sterilization is reasonable if she is certain, but it requires anesthesia and surgical risk in a patient with obesity, diabetes, and CKD. Discuss that pregnancy would be high risk and that lisinopril is teratogenic, so effective contraception is urgent. Screen for pregnancy before placement and provide emergency contraception counseling.
2. She chooses the 52-mg LNG-IUD. Counsel her on expected bleeding, follow-up, and the interaction with her anemia and renal disease.
Read the worked answer
Explain that irregular spotting is common in the first three to six months and that bleeding usually decreases over time; many users become amenorrheic. Because she has iron-deficiency anemia, the LNG-IUD may improve hemoglobin and reduce the need for iron or transfusion. Warn about expulsion, perforation, and infection, and give her signs to return. Confirm a negative pregnancy test before insertion and use backup contraception for seven days if placement occurs after unprotected intercourse earlier in the cycle.
Schedule follow-up to check strings and hemoglobin, and coordinate with nephrology because heavy bleeding can worsen anemia and fluid status. The IUD does not increase VTE risk and does not interact with lisinopril or amlodipine. If she develops severe pain, fever, or heavy bleeding, evaluate for malposition, infection, or perforation. Document that sterilization was discussed and that she chose a reversible method.
3. Fourteen months later she returns with 7 weeks of amenorrhea and a positive urine hCG. The IUD strings are not visible. What is your evaluation and management?
Read the worked answer
Obtain an ultrasound to determine pregnancy location and IUD position. If the pregnancy is intrauterine and the IUD is visible in the cervix or lower uterus, remove it if possible; removal reduces the risk of miscarriage, preterm birth, and infection. If the strings are not visible but the IUD is intrauterine, refer for removal, often by hysteroscopy, while counseling about the risks and benefits. If the pregnancy is ectopic, manage with methotrexate or surgery depending on stability and eligibility.
Because she has CKD, diabetes, hypertension, and prior VTE, stop lisinopril immediately and involve high-risk obstetrics and nephrology. Discuss pregnancy options without coercion, including continuation with intensified monitoring, abortion, or adoption. If she continues, she needs early aspirin for preeclampsia risk, diabetic management, and surveillance for renal deterioration. If she chooses abortion, coordinate a safe setting and account for her medical complexity.